L
9.06
0.15 (1.68%)
| Previous Close | 8.91 |
| Open | 8.85 |
| Volume | 666,791 |
| Avg. Volume (3M) | 1,148,870 |
| Market Cap | 661,265,216 |
| Price / Book | 6.38 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -3.31 |
| Total Debt/Equity (MRQ) | 10.67% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | -88.00 M |
| Levered Free Cash Flow (TTM) | -50.43 M |
| Return on Assets (TTM) | -42.89% |
| Return on Equity (TTM) | -80.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Lexeo Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 121.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Guggenheim, 231.13%) | Buy |
| Median | 19.50 (115.23%) | |
| Low | 13.00 (HC Wainwright & Co., 43.49%) | Buy |
| Average | 20.67 (128.15%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 9.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 18 Dec 2025 | 25.00 (175.94%) | Buy | 9.96 |
| Chardan Capital | 11 Dec 2025 | 17.00 (87.64%) | Buy | 9.80 |
| 05 Nov 2025 | 17.00 (87.64%) | Buy | 8.20 | |
| Cantor Fitzgerald | 01 Dec 2025 | 19.00 (109.71%) | Buy | 8.92 |
| 20 Nov 2025 | 19.00 (109.71%) | Buy | 8.91 | |
| HC Wainwright & Co. | 21 Oct 2025 | 13.00 (43.49%) | Buy | 9.60 |
| 07 Oct 2025 | 15.00 (65.56%) | Buy | 8.34 | |
| Guggenheim | 15 Oct 2025 | 30.00 (231.13%) | Buy | 8.83 |
| Leerink Partners | 07 Oct 2025 | 20.00 (120.75%) | Buy | 8.34 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |